With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

Looking at the data from clinical trials of new GLP-1 agonists, it's clear that patients will need to stay on the drugs to ...

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...

About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...

Breakthrough – or even better, revolutionary breakthrough – is perhaps the most overused term in drug development. But the ...

GLP-1 agonists, widely used for obesity and diabetes management, have been associated with a reduced risk of most ...

It's a big day for Novo Nordisk (NVO) as its CEO Lars Fruergaard Jørgensen testified Tuesday on Capitol Hill over the ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences. Review: ...